![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Low Persistence of Resistance-Associated Variants After 3 Days of Monotherapy With NS5B NNI Site II Inhibitor GS-9669 in Genotype 1 HCV Patients
|
|
|
Reported by Jules Levin
EASL 2014 April 9-13 London, UK
Hadas Dvory-Sobol,1 Viktoria Gontcharova,1 Ross Martin,1 Eric J. Lawitz,2 John G. McHutchison,1 Evguenia S. Svarovskaia,1 Michael D. Miller,1 Hongmei Mo1
1Gilead Sciences, Inc., Foster City, California, USA; 2Alamo Medical Research, San Antonio, Texas, USA
![EASL1.gif](../images/042114/042114-5/EASL1.gif)
![EASL2.gif](../images/042114/042114-5/EASL2.gif)
![EASL3.gif](../images/042114/042114-5/EASL3.gif)
![EASL4.gif](../images/042114/042114-5/EASL4.gif)
![EASL5.gif](../images/042114/042114-5/EASL5.gif)
![EASL6.gif](../images/042114/042114-5/EASL6.gif)
![EASL7.gif](../images/042114/042114-5/EASL7.gif)
![EASL8.gif](../images/042114/042114-5/EASL8.gif)
![EASL9.gif](../images/042114/042114-5/EASL9.gif)
![EASL10.gif](../images/042114/042114-5/EASL10.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|